bYoRNA is cost-efficient, scalable bioproduction of high-quality therapeutic mRNA using eukaryotic cells, particularly recombinant yeast.
bYoRNA has raised $1.8M in total funding. The most recent round was Pre-Seed. The last funding was announced in July 2025.
bYoRNA's investors include Polytechnique Ventures, IRDI SORIDEC Gestion.
bYoRNA is headquartered in Bordeaux, France.
bYoRNA is cost-efficient, scalable bioproduction of high-quality therapeutic mRNA using eukaryotic cells, particularly recombinant yeast.
bYoRNA is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"bYoRNA — Funding & Investors." VCBacked, July 8, 2025, https://www.vcbacked.co/company/byorna. Accessed August 1, 2026.
VCBacked. (2025). bYoRNA — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/byorna
{{cite web |title=bYoRNA — Funding & Investors |url=https://www.vcbacked.co/company/byorna |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated